KR101973063B1 - 지질-기반 나노입자들 - Google Patents

지질-기반 나노입자들 Download PDF

Info

Publication number
KR101973063B1
KR101973063B1 KR1020137029510A KR20137029510A KR101973063B1 KR 101973063 B1 KR101973063 B1 KR 101973063B1 KR 1020137029510 A KR1020137029510 A KR 1020137029510A KR 20137029510 A KR20137029510 A KR 20137029510A KR 101973063 B1 KR101973063 B1 KR 101973063B1
Authority
KR
South Korea
Prior art keywords
aromatic compound
phospholipid
polymer
liposome composition
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020137029510A
Other languages
English (en)
Korean (ko)
Other versions
KR20140074868A (ko
Inventor
아난스 안나프라가다
제이슨 엘. 에릭슨
에릭 에이. 타니품
인드라니 다스굽타
스티븐 씨. 쿡
Original Assignee
보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템
알제카 바이오사이언시스, 엘엘씨
보드 오브 리전츠 오브 더 유니버시티 오브 휴스턴 시스템
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46966277&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101973063(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템, 알제카 바이오사이언시스, 엘엘씨, 보드 오브 리전츠 오브 더 유니버시티 오브 휴스턴 시스템 filed Critical 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템
Publication of KR20140074868A publication Critical patent/KR20140074868A/ko
Application granted granted Critical
Publication of KR101973063B1 publication Critical patent/KR101973063B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0461—Dispersions, colloids, emulsions or suspensions
    • A61K49/0466—Liposomes, lipoprotein vesicles, e.g. HDL or LDL lipoproteins, phospholipidic or polymeric micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dispersion Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020137029510A 2011-04-06 2012-04-06 지질-기반 나노입자들 Expired - Fee Related KR101973063B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161472605P 2011-04-06 2011-04-06
US61/472,605 2011-04-06
PCT/US2012/032649 WO2012139080A2 (en) 2011-04-06 2012-04-06 Lipid-based nanoparticles

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020197007384A Division KR102035187B1 (ko) 2011-04-06 2012-04-06 지질-기반 나노입자들

Publications (2)

Publication Number Publication Date
KR20140074868A KR20140074868A (ko) 2014-06-18
KR101973063B1 true KR101973063B1 (ko) 2019-04-30

Family

ID=46966277

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020137029510A Expired - Fee Related KR101973063B1 (ko) 2011-04-06 2012-04-06 지질-기반 나노입자들
KR1020197007384A Expired - Fee Related KR102035187B1 (ko) 2011-04-06 2012-04-06 지질-기반 나노입자들

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197007384A Expired - Fee Related KR102035187B1 (ko) 2011-04-06 2012-04-06 지질-기반 나노입자들

Country Status (14)

Country Link
US (1) US9801957B2 (enExample)
EP (2) EP3366313A1 (enExample)
JP (3) JP6212032B2 (enExample)
KR (2) KR101973063B1 (enExample)
CN (1) CN104144708B (enExample)
AU (3) AU2012239888B9 (enExample)
BR (1) BR112013025633A2 (enExample)
CA (1) CA2831480C (enExample)
DK (1) DK2694116T3 (enExample)
ES (1) ES2685824T3 (enExample)
MX (1) MX357227B (enExample)
PL (1) PL2694116T3 (enExample)
PT (1) PT2694116T (enExample)
WO (1) WO2012139080A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2694116T3 (pl) 2011-04-06 2018-12-31 Board Of Regents Of The University Of Texas System Nanocząstki na bazie lipidów
MX366972B (es) 2012-01-20 2019-08-01 Ananth Annapragada Metodos y composiciones para caracterizar imagenes medicas en forma objetiva.
US9512092B2 (en) * 2013-12-12 2016-12-06 Albert Einstein College Of Medicine, Inc. Retinoic acid receptor antagonists as chaperone-mediated autophagy modulators and uses thereof
AU2015330824A1 (en) * 2014-10-08 2017-05-25 Ananth Annapragada MRI imaging of amyloid plaque using liposomes
GB201509934D0 (en) 2015-06-08 2015-07-22 King S College London Nanoparticles
CN109414451B (zh) * 2016-05-16 2022-08-12 德克萨斯大学系统董事会 用于作为纳米粒递送tRNA的组合物及其使用方法
EP3548002B1 (en) 2016-11-30 2025-04-30 Texas Children's Hospital Hydrophilic fluorinated molecules for liposomal 19f mri probes with unique mr signatures
US20200261605A1 (en) * 2019-01-24 2020-08-20 Alzeca Biosciences, LLC Functionalized liposomes for imaging misfolded proteins
US11116854B2 (en) * 2020-01-29 2021-09-14 Texas Children's Hospital Targeted contrast agents for MRI of amyloid deposition
US11779664B2 (en) 2020-02-12 2023-10-10 Texas Children's Hospital Targeted contrast agents for MRI of alpha-synuclein deposition
KR20230012461A (ko) 2020-02-12 2023-01-26 텍사스 칠드런스 하스피탈 알파-시누클레인 침착의 mri를 위한 표적화된 조영제

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050152963A1 (en) 2003-12-18 2005-07-14 Joerg Huwyler Liposome compositions
US20070160658A1 (en) * 2005-10-20 2007-07-12 The Penn State Research Foundation Delivery system for diagnostic and therapeutic agents
WO2008054498A2 (en) 2006-04-07 2008-05-08 The Board Of Trustees Of The University Of Illinois Hydrophilic polymer-conjugated lipids for peptide and protein folding disorders

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331751A (en) * 1980-11-17 1982-05-25 Eastman Kodak Company Electrically photosensitive materials and elements for photoelectrophoretic imaging processes
US5204085A (en) 1985-01-08 1993-04-20 Mallinckrodt Medical, Inc. Method for enhancing the safety of metal-ligand chelates as X-ray contrast agents
US5674468A (en) 1992-03-06 1997-10-07 Nycomed Imaging As Contrast agents comprising gas-containing or gas-generating polymer microparticles or microballoons
AU2076895A (en) 1994-03-28 1995-10-17 Daiichi Pharmaceutical Co., Ltd. Liposomes
US6071532A (en) 1996-10-15 2000-06-06 Emory University Synthesis of glycophospholipid and peptide-phospholipid conjugates and uses thereof
ATE287700T1 (de) * 1999-11-30 2005-02-15 Univ Arizona Strahlung-sensitive liposomen
AU2002211517A1 (en) * 2000-10-04 2002-04-15 California Institute Of Technology Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits
US6821504B2 (en) * 2001-05-23 2004-11-23 New York University Detection of alzheimer's amyloid by magnetic resonance imaging
EP1480691A4 (en) 2002-03-05 2007-11-28 Univ State Cleveland AGGLOMERATED PARTICLES FOR THE DISPOSAL OF A MEDICINAL PRODUCT IN AEROSOL FORM
EP1641742A4 (en) 2003-05-01 2006-11-29 Nst Neurosurvival Technologies COMPOUNDS BINDING SELECTIVELY TO MEMBRANES OF APOPTOTIC CELLS
US20100031378A1 (en) 2008-08-04 2010-02-04 Edwards Joel A Novel gene disruptions, compositions and methods relating thereto
US8357351B2 (en) 2004-04-21 2013-01-22 Ananth Annapragada Nano-scale contrast agents and methods of use
US7713517B2 (en) 2004-04-21 2010-05-11 Marval Biosciences, Inc. Compositions and methods for enhancing contrast in imaging
WO2006026184A2 (en) * 2004-08-20 2006-03-09 Washington University Blood brain barrier permeation peptides
US20070292354A1 (en) * 2004-09-23 2007-12-20 Guerbet Contrast Agents Encapsulating Systems for Cest Imaging
US9943481B2 (en) * 2005-05-26 2018-04-17 Biorest Ltd. Compositions and methods using same for delivering agents into a target organ protected by a blood barrier
US20090123047A1 (en) 2007-03-21 2009-05-14 Yfantis Spyros A Method and system for characterizing prostate images
EP1982733A1 (en) 2007-04-17 2008-10-22 Bayer Schering Pharma Aktiengesellschaft Use of a contrast agent for magnetic resonance imaging of endoleaks
WO2009015397A1 (en) 2007-07-26 2009-01-29 Nanoscan Imaging, Llc Methods for imaging using improved nanoparticulate contrast agents
EP2217146A4 (en) 2007-12-05 2015-10-14 Marval Biosciences Inc NANOMETRIC SCALE CONTRAST AGENTS AND METHODS OF USE
EP2242505A4 (en) 2008-01-08 2012-03-07 Biogenerix Ag GLYCOCONJUGATION OF POLYPEPTIDES USING OLIGOSACCHARYLTRANSFERASES
ITMI20081052A1 (it) * 2008-06-10 2009-12-11 Univ Milano Bicocca Liposomi in grado di legare efficacemente il peptide beta-amiloide
AU2009257279A1 (en) * 2008-06-13 2009-12-17 Marval Biosciences, Inc. Imaging of atherosclerotic plaques using liposomal imaging agents
WO2010017094A2 (en) * 2008-07-31 2010-02-11 The General Hospital Corporation CURCUMIN DERIVATIVES FOR AMYLOID-β PLAQUE IMAGING
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
EP2410990A4 (en) 2009-03-19 2015-05-20 Marval Biosciences Inc COMPOSITIONS AND METHODS FOR CONTRAST GAINING IN IMAGING
US9334304B2 (en) * 2009-04-02 2016-05-10 The Johns Hopkins University Self-assembling peptides bearing organic electronic functionality and applications employing the same
ES2620177T3 (es) 2009-10-15 2017-06-27 Guerbet Agentes de formación de imágenes y su uso para el diagnóstico in vivo de enfermedades neurodegenerativas, particularmente la enfermedad de Alzheimer y enfermedades derivadas
JP5746334B2 (ja) 2010-06-16 2015-07-08 シマベイ セラピューティクス， インコーポレーテッド Ｇｐｒ１２０受容体作動薬及びその使用
US8679531B2 (en) 2011-03-02 2014-03-25 Ananth Annapragada Vesicle compositions
PL2694116T3 (pl) 2011-04-06 2018-12-31 Board Of Regents Of The University Of Texas System Nanocząstki na bazie lipidów
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
MX366972B (es) 2012-01-20 2019-08-01 Ananth Annapragada Metodos y composiciones para caracterizar imagenes medicas en forma objetiva.
WO2013164763A2 (en) 2012-04-30 2013-11-07 Innovative Health Diagnostics A biological complex specific for alzheimer's disease detection in vitro and use thereof
MX2015011677A (es) 2013-03-14 2016-07-08 Celtaxsys Inc Inhibidores de leucotrieno a4 hidrolasa.
AU2015330824A1 (en) 2014-10-08 2017-05-25 Ananth Annapragada MRI imaging of amyloid plaque using liposomes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050152963A1 (en) 2003-12-18 2005-07-14 Joerg Huwyler Liposome compositions
US20070160658A1 (en) * 2005-10-20 2007-07-12 The Penn State Research Foundation Delivery system for diagnostic and therapeutic agents
WO2008054498A2 (en) 2006-04-07 2008-05-08 The Board Of Trustees Of The University Of Illinois Hydrophilic polymer-conjugated lipids for peptide and protein folding disorders

Also Published As

Publication number Publication date
KR20190031334A (ko) 2019-03-25
JP6212032B2 (ja) 2017-10-18
US9801957B2 (en) 2017-10-31
CN104144708B (zh) 2017-07-28
AU2017232156C1 (en) 2019-10-24
AU2012239888B9 (en) 2017-10-12
ES2685824T3 (es) 2018-10-11
KR20140074868A (ko) 2014-06-18
KR102035187B1 (ko) 2019-11-08
EP2694116B1 (en) 2018-06-13
AU2017232156B2 (en) 2019-07-11
US20120258044A1 (en) 2012-10-11
PT2694116T (pt) 2018-10-12
AU2019246775A1 (en) 2019-10-31
AU2017232156A1 (en) 2017-10-12
MX357227B (es) 2018-07-02
CN104144708A (zh) 2014-11-12
EP2694116A4 (en) 2015-06-03
JP2018035167A (ja) 2018-03-08
WO2012139080A3 (en) 2014-05-01
BR112013025633A2 (pt) 2017-08-08
WO2012139080A2 (en) 2012-10-11
AU2012239888A1 (en) 2013-11-07
AU2012239888A2 (en) 2014-05-08
EP3366313A1 (en) 2018-08-29
JP2019151664A (ja) 2019-09-12
JP6533813B2 (ja) 2019-06-19
JP2014523854A (ja) 2014-09-18
AU2012239888B2 (en) 2017-06-22
MX2013011231A (es) 2015-03-05
DK2694116T3 (en) 2018-09-03
HK1203827A1 (en) 2015-11-06
CA2831480C (en) 2020-09-29
CA2831480A1 (en) 2012-10-11
PL2694116T3 (pl) 2018-12-31
EP2694116A2 (en) 2014-02-12

Similar Documents

Publication Publication Date Title
KR101973063B1 (ko) 지질-기반 나노입자들
US11141495B2 (en) MRI imaging of amyloid plaque using liposomes
US10124078B2 (en) Lipid-based nanoparticles
HK1203827B (en) Lipid-based nanoparticles
HK40010427A (en) Mri imaging of amyloid plaque using liposomes
BR112017007238B1 (pt) Composição lipossomal compreendendo um conjugado fosfolipídiopolímero-aromático e um agente potencializador de contraste de imagem de ressonância magnética não radioativo para geração de imagem de depósitos amiloides

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

J202 Request for trial for correction [limitation]
PJ0202 Trial for correction

St.27 status event code: A-5-5-V10-V11-apl-PJ0202

J301 Trial decision

Free format text: TRIAL NUMBER: 2019105000067; TRIAL DECISION FOR CORRECTION REQUESTED 20190722

Effective date: 20200114

PJ1301 Trial decision

St.27 status event code: A-5-5-V10-V15-crt-PJ1301

Decision date: 20200114

Appeal event data comment text: Appeal Kind Category : Correction, Appeal Ground Text : 1973063

Appeal request date: 20190722

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2019105000067

G170 Re-publication after modification of scope of protection [patent]
PG1701 Publication of correction

St.27 status event code: A-5-5-P10-P19-oth-PG1701

Patent document republication publication date: 20200130

Republication note text: Request for Public Notice of Correction Statement

Gazette number: 1019730630000

Gazette reference publication date: 20190430

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20220423

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20220423